NEWS & EVENTS

 

MedImmune announces licensing agreement with GamaMabs Pharma

 
MedImmune announces licensing agreement with GamaMabs Pharma

31 October 2017

MedImmune recently announced that it will be entering into a licensing agreement with GamaMabs Pharma, a biotechnology company that develop optimised therapeutic antibodies for the treatment of cancer. The agreement enables GamaMabs to use MedImmune’s PBD portfolio to research and produce an antibody-drug conjugate (ADC) in order to develop potential cancer treatments.

Read the full press release.

Partner Robert Watson and his team advise MedImmune on the IP for their PBD portfolio.